Personalis NeXT Personal Dx Early-Access Program
Personalis has launched an early-access program for its NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy test for detection of molecular residual disease and recurrence in cancer. The assay delivers sensitivity down to approximately 1 parts per million and allows patient-personalized ctDNA panels of up to 1,800 variants. The platform also employs a proprietary signal enhancement and noise suppression methodology. The early-access program is focused on lung cancer, breast cancer, and immunotherapy response monitoring.